The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation

Germline variants within BRCA1 or BRCA2 genes account for approximately 25% of familial aggregations of breast-ovarian cancers. Low or no expression of BRCA1 in breast and ovarian cancers is associated with a good clinical response to treatment with platinum therapies and PARP1 inhibitors. Recent st...

Descripción completa

Detalles Bibliográficos
Autores principales: Strumidło, Agnieszka, Skiba, Sylwia, Scott, Rodney J., Lubiński, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622493/
https://www.ncbi.nlm.nih.gov/pubmed/29021870
http://dx.doi.org/10.1186/s13053-017-0076-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5622493/
https://www.ncbi.nlm.nih.gov/pubmed/29021870
http://dx.doi.org/10.1186/s13053-017-0076-7

Ejemplares similares